A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo

Eric C. McGary, Amy Heimberger, Lisa Mills, Kristy Weber, Gary W. Thomas, Mikhail Shtivelband, Dina Chelouche Lev, Menashe Bar-Eli

Research output: Contribution to journalArticle

Abstract

Purpose: The melanoma cellular adhesion molecule, also known as MUC18, is highly expressed on several tumors, including bone sarcomas. The level of MUC18 expression has been found to correlate directly with tumor progression and metastatic potential. These observations have established MUC18 as a candidate mediator of tumor growth and metastasis, and suggest that blockade of MUC18 might be a potential target for immunotherapy against several MUC18-expressing tumors, including human bone sarcomas. Experimental Design: To investigate whether blockade of MUC18 might be a potential target for immunotherapy against osteosarcoma, we have recently developed a fully human anti-MUC18 antibody, ABX-MA1. We studied the effect of ABX-MA1 on growth, adhesion, invasion, and metastasis of human osteosaroma cells both in vitro and in vivo. Results: MUC18 was widely expressed on both osteosarcoma and Ewing's sarcoma cells. ABX-MA1 had no effect on the proliferation of osteosarcoma cells in vitro, nor did it significantly inhibit the growth of KRIB human osteosarcoma cells when they were orthotopically implanted into the tibias of nude mice. However, after 6 weeks, significantly fewer ABX-MA1-treated mice developed spontaneous pulmonary metastases than did IgG-treated control mice. Additionally, ABX-MA1 decreased the invasion of osteosarcoma cells through Matrigel-coated filters and disrupted homotypic adhesion between osteosarcoma cells and their heterotypic interaction with human vascular endothelial cells. Conclusions: Our findings demonstrate that MUC18 plays a central role in the metastasis of osteosarcoma and suggest that targeted inhibition of this antigen by ABX-MA1 may be a novel immunotherapeutic approach in the management of this tumor.

Original languageEnglish (US)
Pages (from-to)6560-6566
Number of pages7
JournalClinical Cancer Research
Volume9
Issue number17
StatePublished - Dec 15 2003
Externally publishedYes

Fingerprint

Osteosarcoma
Neoplasm Metastasis
Lung
Antibodies
Neoplasms
Sarcoma
Immunotherapy
Growth
Bone and Bones
Ewing's Sarcoma
Tibia
Nude Mice
Anti-Idiotypic Antibodies
Melanoma
Research Design
Endothelial Cells
Immunoglobulin G
Cell Proliferation
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

McGary, E. C., Heimberger, A., Mills, L., Weber, K., Thomas, G. W., Shtivelband, M., ... Bar-Eli, M. (2003). A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo. Clinical Cancer Research, 9(17), 6560-6566.

A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo. / McGary, Eric C.; Heimberger, Amy; Mills, Lisa; Weber, Kristy; Thomas, Gary W.; Shtivelband, Mikhail; Lev, Dina Chelouche; Bar-Eli, Menashe.

In: Clinical Cancer Research, Vol. 9, No. 17, 15.12.2003, p. 6560-6566.

Research output: Contribution to journalArticle

McGary, EC, Heimberger, A, Mills, L, Weber, K, Thomas, GW, Shtivelband, M, Lev, DC & Bar-Eli, M 2003, 'A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo', Clinical Cancer Research, vol. 9, no. 17, pp. 6560-6566.
McGary, Eric C. ; Heimberger, Amy ; Mills, Lisa ; Weber, Kristy ; Thomas, Gary W. ; Shtivelband, Mikhail ; Lev, Dina Chelouche ; Bar-Eli, Menashe. / A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 17. pp. 6560-6566.
@article{859fa57923a9406ead7cfcda371ccd2c,
title = "A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo",
abstract = "Purpose: The melanoma cellular adhesion molecule, also known as MUC18, is highly expressed on several tumors, including bone sarcomas. The level of MUC18 expression has been found to correlate directly with tumor progression and metastatic potential. These observations have established MUC18 as a candidate mediator of tumor growth and metastasis, and suggest that blockade of MUC18 might be a potential target for immunotherapy against several MUC18-expressing tumors, including human bone sarcomas. Experimental Design: To investigate whether blockade of MUC18 might be a potential target for immunotherapy against osteosarcoma, we have recently developed a fully human anti-MUC18 antibody, ABX-MA1. We studied the effect of ABX-MA1 on growth, adhesion, invasion, and metastasis of human osteosaroma cells both in vitro and in vivo. Results: MUC18 was widely expressed on both osteosarcoma and Ewing's sarcoma cells. ABX-MA1 had no effect on the proliferation of osteosarcoma cells in vitro, nor did it significantly inhibit the growth of KRIB human osteosarcoma cells when they were orthotopically implanted into the tibias of nude mice. However, after 6 weeks, significantly fewer ABX-MA1-treated mice developed spontaneous pulmonary metastases than did IgG-treated control mice. Additionally, ABX-MA1 decreased the invasion of osteosarcoma cells through Matrigel-coated filters and disrupted homotypic adhesion between osteosarcoma cells and their heterotypic interaction with human vascular endothelial cells. Conclusions: Our findings demonstrate that MUC18 plays a central role in the metastasis of osteosarcoma and suggest that targeted inhibition of this antigen by ABX-MA1 may be a novel immunotherapeutic approach in the management of this tumor.",
author = "McGary, {Eric C.} and Amy Heimberger and Lisa Mills and Kristy Weber and Thomas, {Gary W.} and Mikhail Shtivelband and Lev, {Dina Chelouche} and Menashe Bar-Eli",
year = "2003",
month = "12",
day = "15",
language = "English (US)",
volume = "9",
pages = "6560--6566",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo

AU - McGary, Eric C.

AU - Heimberger, Amy

AU - Mills, Lisa

AU - Weber, Kristy

AU - Thomas, Gary W.

AU - Shtivelband, Mikhail

AU - Lev, Dina Chelouche

AU - Bar-Eli, Menashe

PY - 2003/12/15

Y1 - 2003/12/15

N2 - Purpose: The melanoma cellular adhesion molecule, also known as MUC18, is highly expressed on several tumors, including bone sarcomas. The level of MUC18 expression has been found to correlate directly with tumor progression and metastatic potential. These observations have established MUC18 as a candidate mediator of tumor growth and metastasis, and suggest that blockade of MUC18 might be a potential target for immunotherapy against several MUC18-expressing tumors, including human bone sarcomas. Experimental Design: To investigate whether blockade of MUC18 might be a potential target for immunotherapy against osteosarcoma, we have recently developed a fully human anti-MUC18 antibody, ABX-MA1. We studied the effect of ABX-MA1 on growth, adhesion, invasion, and metastasis of human osteosaroma cells both in vitro and in vivo. Results: MUC18 was widely expressed on both osteosarcoma and Ewing's sarcoma cells. ABX-MA1 had no effect on the proliferation of osteosarcoma cells in vitro, nor did it significantly inhibit the growth of KRIB human osteosarcoma cells when they were orthotopically implanted into the tibias of nude mice. However, after 6 weeks, significantly fewer ABX-MA1-treated mice developed spontaneous pulmonary metastases than did IgG-treated control mice. Additionally, ABX-MA1 decreased the invasion of osteosarcoma cells through Matrigel-coated filters and disrupted homotypic adhesion between osteosarcoma cells and their heterotypic interaction with human vascular endothelial cells. Conclusions: Our findings demonstrate that MUC18 plays a central role in the metastasis of osteosarcoma and suggest that targeted inhibition of this antigen by ABX-MA1 may be a novel immunotherapeutic approach in the management of this tumor.

AB - Purpose: The melanoma cellular adhesion molecule, also known as MUC18, is highly expressed on several tumors, including bone sarcomas. The level of MUC18 expression has been found to correlate directly with tumor progression and metastatic potential. These observations have established MUC18 as a candidate mediator of tumor growth and metastasis, and suggest that blockade of MUC18 might be a potential target for immunotherapy against several MUC18-expressing tumors, including human bone sarcomas. Experimental Design: To investigate whether blockade of MUC18 might be a potential target for immunotherapy against osteosarcoma, we have recently developed a fully human anti-MUC18 antibody, ABX-MA1. We studied the effect of ABX-MA1 on growth, adhesion, invasion, and metastasis of human osteosaroma cells both in vitro and in vivo. Results: MUC18 was widely expressed on both osteosarcoma and Ewing's sarcoma cells. ABX-MA1 had no effect on the proliferation of osteosarcoma cells in vitro, nor did it significantly inhibit the growth of KRIB human osteosarcoma cells when they were orthotopically implanted into the tibias of nude mice. However, after 6 weeks, significantly fewer ABX-MA1-treated mice developed spontaneous pulmonary metastases than did IgG-treated control mice. Additionally, ABX-MA1 decreased the invasion of osteosarcoma cells through Matrigel-coated filters and disrupted homotypic adhesion between osteosarcoma cells and their heterotypic interaction with human vascular endothelial cells. Conclusions: Our findings demonstrate that MUC18 plays a central role in the metastasis of osteosarcoma and suggest that targeted inhibition of this antigen by ABX-MA1 may be a novel immunotherapeutic approach in the management of this tumor.

UR - http://www.scopus.com/inward/record.url?scp=0347594110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347594110&partnerID=8YFLogxK

M3 - Article

C2 - 14695161

AN - SCOPUS:0347594110

VL - 9

SP - 6560

EP - 6566

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -